Castle Biosciences (CSTL) Accounts Payables (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Accounts Payables data on file, last reported at $15.0 million in Q1 2026.

• Quarterly Accounts Payables rose 76.88% year-over-year to $15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.0 million (up 76.88% YoY) and the FY2025 annual result came in at $18.7 million, up 171.13% from the prior year.
• Accounts Payables eased to $15.0 million in Q1 2026 per CSTL's latest filing, from $18.7 million in the prior quarter.
• The five-year high for Accounts Payables was $18.7 million in Q4 2025, with the low at $3.3 million in Q2 2022.
• Average Accounts Payables over 5 years is $8.9 million, with a median of $8.5 million recorded in 2025.
• Year-over-year, Accounts Payables surged 200.57% in 2023 and slumped 32.79% in 2024.
• Castle Biosciences' Accounts Payables stood at $4.7 million in 2022, then soared by 117.04% to $10.3 million in 2023, then slumped by 32.79% to $6.9 million in 2024, then jumped by 171.13% to $18.7 million in 2025, then slipped by 19.63% to $15.0 million in 2026.
• Business Quant data shows CSTL's Accounts Payables at $15.0 million in Q1 2026, $18.7 million in Q4 2025, and $12.2 million in Q3 2025.